Background
Glioblastoma multiforme (GBM) is a highly malignant brain tumor characterized by rapid progression and poor patient prognosis. The search for novel molecular targets is critical to developing more effective therapies. UniProt entry P84243 corresponds to a human protein with limited characterization in the context of GBM. Preliminary expression profiling suggests that P84243 may be differentially expressed in GBM tissues compared to normal brain, indicating a potential involvement in tumor biology. No clinical development programs targeting P84243 have been identified, positioning it as a putative target that warrants experimental validation.
Data-mining rationale
This candidate was identified by cross-referencing UniProt’s reviewed human protein entries annotated for glioblastoma multiforme with 724 microarray datasets in the NCBI Gene Expression Omnibus (GEO). Several datasets (GDS:200317497, GDS:200273558, GDS:200320501, GDS:200318047, GDS:200318046) include expression profiles relevant to GBM and show signals implicating P84243. The repeated detection of P84243 across multiple independent datasets supports its candidacy as a molecular target meriting further investigation.
Why prior analyses may have missed this
Many of the original GEO microarray studies predate the adoption of modern empirical-Bayes statistical methods such as limma, which improve the detection of differentially expressed genes while controlling for false discovery rates. Earlier analyses often lacked rigorous multiple-testing correction, potentially overlooking subtle but biologically meaningful expression changes. As a result, P84243 may have been underappreciated or missed in prior transcriptomic analyses of GBM. Re-analysis of these datasets using limma with Benjamini-Hochberg false discovery rate correction could more robustly establish the differential expression and relevance of P84243.
Reasoning for further validation
Given the consistent expression signals for P84243 in GBM across multiple datasets, several experimental steps are recommended to validate its candidacy as a putative target. First, re-analyzing the matched GEO datasets using limma and stringent multiple-testing correction will refine the statistical evidence for differential expression. Second, validating P84243 expression in independent GBM cohorts by quantitative PCR will confirm reproducibility. Third, assessing tissue specificity through resources such as GTEx and the Human Protein Atlas will provide context regarding normal and tumor expression patterns. Fourth, bioinformatic pathway analyses using STRING or OmniPath can elucidate potential functional interactions and signaling pathways involving P84243. Finally, if validated, evaluating druggability via databases like DGIdb and ChEMBL may inform future therapeutic exploration. Collectively, these steps will clarify whether P84243 represents a viable molecular target in GBM warranting further preclinical investigation.